Comparative Pharmacology
Head-to-head clinical analysis: LARYNGOTRACHEAL ANESTHESIA KIT versus LIDOSITE TOPICAL SYSTEM KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LARYNGOTRACHEAL ANESTHESIA KIT versus LIDOSITE TOPICAL SYSTEM KIT.
LARYNGOTRACHEAL ANESTHESIA KIT vs LIDOSITE TOPICAL SYSTEM KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine and tetracaine are sodium channel blockers, inhibiting nerve impulse conduction, providing local anesthesia. Epinephrine is a vasoconstrictor that reduces systemic absorption and prolongs duration.
Lidocaine is an amide-type local anesthetic that stabilizes neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting the initiation and conduction of nerve impulses.
4 mL of 4% lidocaine (160 mg) via atomizer or nebulizer for topical laryngotracheal anesthesia, with additional 2 mL aliquots as needed, not to exceed 4.5 mg/kg total dose.
Apply up to 3 patches topically once daily for up to 12 hours per day. Maximum 3 patches (210 mg lidocaine) per day.
None Documented
None Documented
Lidocaine terminal half-life: 1.5–2 hours (normal hepatic function); prolonged to 3–5 hours in heart failure or hepatic disease. Tetracaine: 2–3 hours.
1.5-2 hours (terminal); prolonged in hepatic dysfunction or heart failure
Renal excretion of lidocaine and its metabolites (primarily monoethylglycinexylidide (MEGX) and glycinexylidide (GX)); <10% unchanged. Biliary/fecal excretion minimal (<5%).
Renal (80-90% as metabolites, <10% unchanged), biliary/fecal (minor, <5%)
Category C
Category C
Local Anesthetic
Local Anesthetic